CMPX קפיטליזציה חשבונאית Compass Therapeutics, Inc.

Compass Therapeutics (CMPX) develops innovative anti-tumor agents, leveraging outsourced manufacturing and testing to minimize capital expenditures. The company generates revenue through the licensing of durable antibody technologies, while management is currently revising the priorities of its clinical programs. This price chart at the 0.17 level confirms the impact of this strategy and management's real-time adaptation to new trial data.

Book value reflects the value of net assets, determining the intrinsic value of the business through the difference between all assets and liabilities. This indicator separates the real value of resources from market noise. By analyzing book value dynamics, an investor assesses the speed at which capital is transformed into technological potential. For Compass Therapeutics (CMPX), this trend is critical due to the absence of revenue. The metric demonstrates the company's ability to sustain antibody development using raised funds.